Switch theme
Sign up to access all valuation multiples
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
2015
205
LTM Revenue $84.2M
LTM EBITDA -$26.4M
$111M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Akoya Biosciences has a last 12-month revenue of $84.2M and a last 12-month EBITDA of -$26.4M.
In the most recent fiscal year, Akoya Biosciences achieved revenue of $81.7M and an EBITDA of -$37.1M.
Akoya Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Akoya Biosciences valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $96.6M | $81.7M | XXX | XXX | XXX |
| Gross Profit | $43.4M | $56.3M | XXX | XXX | XXX |
| Gross Margin | 45% | 69% | XXX | XXX | XXX |
| EBITDA | -$45.6M | -$37.1M | XXX | XXX | XXX |
| EBITDA Margin | -47% | -45% | XXX | XXX | XXX |
| Net Profit | -$70.6M | -$63.3M | XXX | XXX | XXX |
| Net Margin | -73% | -78% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Akoya Biosciences's stock price is $1.
Akoya Biosciences has current market cap of $62.3M, and EV of $111M.
See Akoya Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $111M | $62.3M | XXX | XXX | XXX | XXX | $-0.99 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Akoya Biosciences has market cap of $62.3M and EV of $111M.
Akoya Biosciences's trades at 1.3x LTM EV/Revenue multiple, and -4.2x LTM EBITDA.
Analysts estimate Akoya Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Akoya Biosciences and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $111M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | -3.0x | XXX | XXX | XXX |
| P/E | -1.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAkoya Biosciences's NTM/LTM revenue growth is 11%
Akoya Biosciences's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Akoya Biosciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Akoya Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Akoya Biosciences and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -15% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -45% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -19% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -35% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 24% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 109% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Akoya Biosciences acquired XXX companies to date.
Last acquisition by Akoya Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Akoya Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Akoya Biosciences founded? | Akoya Biosciences was founded in 2015. |
| Where is Akoya Biosciences headquartered? | Akoya Biosciences is headquartered in United States of America. |
| How many employees does Akoya Biosciences have? | As of today, Akoya Biosciences has 205 employees. |
| Who is the CEO of Akoya Biosciences? | Akoya Biosciences's CEO is Mr. Brian McKelligon. |
| Is Akoya Biosciences publicy listed? | Yes, Akoya Biosciences is a public company listed on NAS. |
| What is the stock symbol of Akoya Biosciences? | Akoya Biosciences trades under AKYA ticker. |
| When did Akoya Biosciences go public? | Akoya Biosciences went public in 2021. |
| Who are competitors of Akoya Biosciences? | Similar companies to Akoya Biosciences include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Akoya Biosciences? | Akoya Biosciences's current market cap is $62.3M |
| What is the current revenue of Akoya Biosciences? | Akoya Biosciences's last 12-month revenue is $84.2M. |
| What is the current EBITDA of Akoya Biosciences? | Akoya Biosciences's last 12-month EBITDA is -$26.4M. |
| What is the current EV/Revenue multiple of Akoya Biosciences? | Current revenue multiple of Akoya Biosciences is 1.3x. |
| What is the current EV/EBITDA multiple of Akoya Biosciences? | Current EBITDA multiple of Akoya Biosciences is -4.2x. |
| What is the current revenue growth of Akoya Biosciences? | Akoya Biosciences revenue growth between 2023 and 2024 was -15%. |
| Is Akoya Biosciences profitable? | Yes, Akoya Biosciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
